Clinical Course after Intravitreal Bevacizumab Injection in Ischemic Central Retinal Vein Obstruction
Journal of the Korean Ophthalmological Society
; : 1202-1207, 2011.
Article
de Ko
| WPRIM
| ID: wpr-9182
Bibliothèque responsable:
WPRO
ABSTRACT
PURPOSE: To determine the clinical outcome of intravitreal bevacizumab injection in patients with ischemic central retinal vein obstruction (CRVO). METHODS: The present study was conducted retrospectively on 56 eyes of 56 patients who were diagnosed with CRVO and classified according to ischemic and non-ischemic type and underwent an intravitreal bevacizumab injection. The present study measured changes in visual acuity and central macular thickness, neovascularization in the anterior segment, development of neovascular glaucoma and other clinical complications. RESULTS: The average number of bevacizumab injections in both groups was 2.07 and 1.62 in the ischemic type. No patients developed neovascular glaucoma in the non-ischemic type group, 14 of 26 eyes in the ischemic type group developed neovascular glaucoma and the mean time to diagnosis was 28.75 weeks. log MAR visual acuity of the ischemic type group prior to injection was 1.56 +/- 0.65 on average which improved to 1.44 +/- 0.97 (p = 0.45). CONCLUSIONS: Intravitreal bevacizumab injection improves the condition of cystic macular edema clinically, but does not affect the development of neovascular glaucoma and improvement of visual acuity in ischemic type CRVO.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Veine centrale de la rétine
/
Acuité visuelle
/
Glaucome néovasculaire
/
Oedème maculaire
/
Études rétrospectives
/
Oeil
/
Anticorps monoclonaux humanisés
/
Bévacizumab
Type d'étude:
Observational_studies
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Journal of the Korean Ophthalmological Society
Année:
2011
Type:
Article